The Wilms' tumor protein, WT1, represses transcription from several growth factor genes. WT1 transcription is regulated in erythroid and myeloid lineages by the transcription factor GATA-1. Using a sensitive, isotopic duplex RT-PCR procedure amplifying WT1 or GATA-1 together with ␤-actin as the internal control in a single reaction mix, we quantitated the expression of WT1 and GATA-1 mRNA of 16 patients with myelodysplastic syndrome (MDS), 56 with acute myeloid leukemia (AML) and 22 with acute lymphoblastic leukemia (ALL). K562 was used as reference positive control for this cell line expresses both WT1 and GATA-1. Among MDS patients, increased WT1 expression was found in refractory anemia with excess blast (RAEB) and RAEB in transformation (RAEB-T) subtypes compared to the normal controls, whereas WT1 expression in refractory anemia (RA) was not different from the normal control level. All of AML cases of subtypes M0, M1, M2 and M3 expressed WT1 more than three times the normal WT1 level. Subtypes M4 to M7 showed significantly lower WT1 levels than M1 to M3 and AML cases with CD14 + expressed less WT1 than CD14 − . Higher than normal WT1 levels were also expressed in cases of ALL.
Introduction
Wilms' tumor (WT), or nephroblastoma, is a childhood malignancy of renal blastemal cells. These mesenchymal cells normally differentiate to form nephrons when induced by the ureteric bud. 1, 2 Cytogenetic studies have provided evidence of chromosomal localization when deletions in a region of the short arm of chromosome 11 at 11p13 were commonly found in patients with the WAGR syndrome of Wilms' tumor, aniridia, genito-urinary abnormalities and mental retardation. 3, 4 The human Wilms' tumor gene (WT1) is a potential tumor suppressor gene that encodes a transcription factor containing a proline-rich amino terminus and four contiguous zinc fingers of the cys 2 -his 2 type at its carboxy end. The proline-rich region functions as a transcriptional repressor, 5 and the zinc finger region binds DNA in vitro. 6, 7 This WT1 gene product represses transcription from promoters of many growth factors and receptor genes. 8, 9 WT1 has also been shown to repress the promotors of several genes expressed in hematopoietic cells (ie CSF-1, TGF␤-1, RAR␣, c-myc, and bcl-2). [10] [11] [12] This suggests that WT1 may function as a transcriptional repressor of genes that control hematopoietic proliferation, differentiation or both.
The expression pattern of WT1 during development is limited to cell types of mesothelial origin. 13, 14 A homozygous point mutation within the WT1 gene in human mesothelioma has been reported. 13 We have previously shown that WT1 is strongly expressed in immature CD34
+ bone marrow (BM) stem cells but it is only weakly expressed in normal mature blood cells. 15 Our analysis of murine hematopoietic WT1 expression in embryonic tissues has shown that WT1 transcripts are highest in the liver at 12.5 dpc, suggesting that WT1 is expressed in the primary hematopoietic organ during definitive hematopoiesis. WT1 expression in hematopoietic malignancies has been reported, 16, 17 and the high WT1 expression levels correlate well with a poor prognosis of patients with acute leukemia. 18 Wu et al 19 identified a hematopoietic enhancer located 3Ј of the WT1 gene, and showed that GATA-1 is able to transactivate this enhancer. The GATA-1 gene is located on the X chromosome and encodes a hematopoietic transcription factor. 20, 21 Recently, Zhang et al 22 demonstrated that the 3Ј WT1 enhancer is responsible for the expression of WT1 in the erythroid lineage and confirmed that this enhancer is transactivated by GATA-1. In addition, another enhancer located at the third intron of WT1 (intronic enhancer) is responsible for the expresssion of WT1 in the myeloid granulocytic lineage and is also GATA-1-responsive. 22 Coexpression of WT1 and GATA-1 mRNA was observed in murine spleen, K562, HEL cells and human acute leukemia. 19, 23 GATA-1 protein recognizes the TGATAA/G DNA consensus sequence, the site initially identified in the promoters of erythroid-␣ and -␤ globin genes and their control regions, as well as in the promoter of erythropoietin receptor. 21 Gene targeting in mouse embryonic stem cells at the GATA-1 locus has shown that GATA-1 is essential for erythroid development. 21, [24] [25] [26] The GATA-1 binding sites are also located within the promoter and enhancer regions of WT1 8, 22 as well as in globin gene. 27 From this accumulating evidence, GATA-1 is thought to play a major role in the regulation of WT1 expression in the hematopoietic system.
In this report, we examined WT1 and GATA-1 expression and the factors influencing such expression in myelodysplastic syndrome (MDS), a condition previously designated as preleukemia, and in acute leukemia (acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) ). Our results support a role for WT1 and GATA-1 in abnormal hematopoiesis and acute leukemia.
Materials and methods

Patients
This study group included 16 patients with MDS, 56 with AML, 22 with ALL and nine normal controls. MDS and human leukemia were classified according to the French-AmericanBritish (FAB) [28] [29] [30] [31] and morphologic, immunologic and cytogenetic (MIC) 32, 33 criteria. Among 16 cases of MDS there were seven cases of refractory anemia (RA), four RA with excess blasts (RAEB), two RA with excess blasts in transformation (RAEB-T) and three with chronic myelomonocytic leukemia (CMML). Of the 56 cases of AML, 55 were de novo AML patients and one had CML in blastic transformation to AML. Bone marrow (BM) and peripheral blood (PB) were obtained from the patients before they received chemotherapeutic treatment. PB specimens were obtained from all 94 patients, whereas both BM and PB specimens were obtained from 44 of the 94 patients. Leukopheresed leukemic blood samples were obtained from 37 of the remaining 50 patients, so were WBC-enriched. Normal PB were used as controls for WT1 and GATA-1 expression.
Mononuclear cells were separated from leukemic and normal heparinized PB and BM aspirates by Ficoll-Hypaque centrifugation. Total RNA was isolated by the method of Chomczynski and Sacchi 34 by using STAT-60 (Tel Test, Friendswood, TX, USA) according to the manufacturer's recommendations. Quality of the RNA was analyzed by electrophoresis in a 1% agarose-formaldehyde minigel.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
Reverse transcription was carried out as previously described. 18 In brief, 1 g of total RNA was diluted in diethylpyrocarbonate (DEPC)-treated water, denatured at 70°C for 10 min and then quick-chilled on ice. Reverse transcription (RT) was performed by adding RT reaction cocktail containing 50 mm Tris-HC1 (pH 8.3), 70 mm KCl, 3 mm MgCl 2 , 10 mm dithiothreitol, 200 U of Moloney murine leukemia virus reverse transcriptase (Superscript II; Life Technology, Gaithersburg, MD, USA), 500 mm each dNTP (Pharmacia, Piscataway, NJ, USA), 50 m random hexamer primer, and 33 U of RNase inhibitor (Boehringer, Mannheim, Germany). The reaction was incubated at 37°C for 90 min and then heated at 95°C for 7 min. After quick-chilling, the cDNA products were stored at −20°C before use. PCR amplification of one-half of the reverse transcription reaction was performed as duplex PCR for amplifying either WT1 and ␤-actin (35 cycles) or GATA-1 and ␤-actin (30 cycles). ␤-Actin was used as the RNA internal control of the reaction. The optimal conditions for amplification of duplex PCR (␤-actin-WT1 and ␤-actin-GATA-1) were described previously 23 with a thermal cycler (PerkinElmer, Norwalk, CT, USA). One microcurie of ␣ 32 P-dCTP (spec act = 3000 Ci/mmol) was added to each 50 l PCR reaction for quantitation purposes. Primer concentrations were 200 nm for WT1 and GATA-1 and to compensate for the over abundance of ␤-actin mRNA we used 1/10th concentration of ␤-actin primer (20 nm). PCR amplification was carried out using the following primer pairs: 5Ј ␤-actin (5Ј-GTGGGGCGCCCCAGGCACCA-3Ј), 3Ј ␤-actin (5Ј-GTCCTTAATGTCACGCACGATTTC-3Ј). 5Ј WT1 (exon 7) (5Ј-GGCATCTGAGACCAGTGAAA-3Ј), 3Ј WT1 (exon 10) (5Ј-GAGAGTCAGACTTGAAAGCAGT-3Ј); 5Ј GATA-1 (exon 5) (5Ј-ATTGTCAGTAAACGGGCAGG-3Ј) 3Ј-GATA-1 (exon 6) (5Ј-CACCACCATAAAGCCACCAGC-3Ј). Distilled DEPC water was used as negative control and RNA isolated from K-562 cells was used as a positive control for both WT1 and GATA-1 expression. One-fifth of WT1 PCR products were separated in a 1.5% low melting point agarose gel containing ethidium bromide (0.1 g/ml) and photographed under ultraviolet illumination. Figure 1 shows examples of RT-PCR-amplified WT1 expression. One-half of the GATA-1 PCR products were separated on 4% polyacrylamide gel electrophoresis. Sizes of the PCR products were 480 bp of WT1 zinc finger region (exon 7 to exon 10), 226 bp of GATA-1 coding sequence, and 541 bp of ␤-actin coding sequence. Both agarose and polyacrylamide gels were dried and the radioactivity was quantitated by phosphoimaging (Molecular Dynamics, Sunnyvale, CA, USA). The ratio between the ␣ 32 P-dCTP-labeled WT1 and ␤-actin products as well as the ratio between GATA-1 and ␤-actin products were calculated for each sample. The ratios for each PB and BM sample were normalized by dividing each ratio by the ratio for the positive control K-562 for each experimental assay.
Chromosome analysis
Standard cytogenetic techniques were used 35 and karyotypes were described according to International System for Human Cytogenetic Nomenclature (ISCN) recommendation. 36 
Statistical analysis
Statistical evaluation of WT1 and GATA-1 expression levels were accomplished by Mann-Whitney U test, using NPAR module of the SYSTAT computer software. Results were computed as mean values ± standard error of the mean. Correlation between bone marrow and peripheral blood levels of WT1 and GATA-1 expression were tested by regression analysis -MGLH module of the SYSTAT programme. Relationship between WT1 gene expression levels and cytogenetic findings were analyzed by Yates corrected Chi-square test.
Results
We report here the WT1 and GATA-1 gene expression in 103 PB samples from 16 patients with myelodysplastic syndromes, 55 with de novo AML, one with AML following CML blastic transformation, 22 with ALL and nine normal individuals. Bone marrow (BM) WT1 and GATA-1 expression levels were also examined in 44 of the 94 cases of MDS and acute leuke- Normalized ratios of WT1 to ␤-actin levels were used as internal controls for each sample. The sample ratios were normalized to K562 cell ratios as described in the text. Each bar represents the mean; the standard error of the mean is depicted above the bar. mias. The relationship between WT1 expression level and cytogenetic/immunophenotypic findings are described.
WT1 and GATA-1 expression in normal individuals
Average PB MNC levels of WT1 from nine normal individuals was 0.12 ± 0.02 (range 0.02 to 0.20) (Figure 2) . The same average level of 0.12 ± 0.02 was found for PB MNC GATA-1 gene expression (range 0.09 to 0.17). The individual normal control level of WT1 and GATA-1 are shown in Table 1 .
WT1 and GATA-1 expression in myelodysplastic syndromes
Among MDS patients, higher WT1 levels in PB were found in the subtypes RAEB and RAEB-T ( Figure 2 , Table 2 ), with the mean values of 0.46 ± 0.12 (n = 6) or 3.8 times higher than the average normal control level (P = 0.029). Four of the six RAEB and RAEB-T cases strongly expressed WT1 and their WT1 gene expression levels were more than 0.35 (Table 2) . In contrast, WT1 expression levels in RA was not different from normal control and the average WT1 levels in RA (n = 7) and CMML (n = 3) were 0.19 and 0.26, respectively. Among the 16 MDS patients, three of seven RA, four of six RAEB/RAEB-T and two of three CMML cases exhibited elevated PB WT1 levels. The WT1 expression levels in each of MDS subtypes, as well as WBC counts and the percentage of PB and BM blasts, are given in Table 2 . Elevated PB GATA-1 levels were found in two of seven RA, three of six RAEB/RAEB-T, and none of CMML cases. RAEB and RAEB-T expressed relatively higher level of WT1 than RA (P = 0.086). However, the overall PB GATA-1 gene expression levels in MDS were not different from normal controls, with the average value of 0.19 ± 0.03. Since the majority of PB samples were obtained by leukapheresis of leukemic and MDS patients, a comparison was made between the paired BM and PB samples for both WT1 and GATA-1 expression in 12 MDS and 32 acute leukemia cases summarized in Table 3 , showed a good correlation between the BM and PB levels of both WT1 and GATA-1. One MDS case of RAEB subtype (patient No. 50) exhibited elevation of both WT1 (0.72) and GATA-1 (0.44) transcript levels in peripheral blood MNC. Complex chromosome abnormalities were also detected in this patient. MDS patients whose PB strongly expressed WT1 also showed the most complicated chromosomal abnormalities.
Comparison of the cytogenetic findings in each MDS patient with different WT1 levels are in Table 4 . Although MDS is a rare hematological condition and the number of MDS patients in this study is rather small (n = 16), we found a relationship between MDS subtypes, WT1 gene expression levels and cytogenetic findings among these patients. When 15 cases with MDS were analyzed, the MDS cases whose WT1 levels were lower than 0.35 showed normal diploid karyotypes or a single chromosome abnormality while MDS cases with WT1 expression higher than 0.35 exhibited complex chromosome aberrations ( 2 = 7.85, P = 0.007). Six of the seven RA cases had either normal diploid karyotypes or a single chromosome defects (loss of Y or gain 8). Chromosome analysis was not possible in one patient with RA (No. 39). Four patients with RAEB/RAEB-T whose PB WT1 expression levels were above 0.35 exhibited complex chromosomal abnormalities (patients 28, 30, 36 and 50). Two of them had very high PB WT1 expression levels (0.88, patient 36; and 0.72, patient 50) and showed several types of both numerical and structural chromosome aberrations. Addition of the short arms of chromosome 11 (add(11)(p15)) and 17 (add(17)(p13)), as well as deletions of the long arms of chromosome 5 (del(5)(q32)) and 20(del(20)(q11.2) were detected in patient No. 36. In patient No. 50, the clonal structural chromosome defect includes t(7;17)(q21;q11.1) and t(1;16)(p36.3;p13.3) in combination with many numerical defects. In addition, del(5)(q13) and i(17)(q10) were observed in patient 28 and del(12)(p12) in patient No. 30. The other two RAEB/RAEB-T cases (patients 29 and 33) whose PB had normal or slightly elevated WT1 levels, showed normal diploid karyotypes. A normal diploid karyotype, however, was observed in a CMML patient who had an elevated WT1 level of 0.53 (patient 62).
WT1 and GATA-1 expression in acute myeloid leukemia
Peripheral blood WT1 and GATA-1 expression levels in MNC of 56 AML patients are summarized in Table 5 . Increased PB WT1 gene expression levels were found in 50 of 56 cases (89%) as compared with levels in the normal controls ( Figure  2) . The average WT1 level in patients with de novo AML was 0.7 (n = 54) or 5.8 times the mean normal control value (P Ͻ (8) 105 (17) 28 (16) 83 (4.4) 69 (6.9) M2 (12) 85 (12) 23 (6) 83 (6.1) 57 (5.0) M3 (3) 54 (16) 33 (15) 62 (17) 54 (20) M4 (12) 48 (10) 15 (3) 66 (6.4) 43 (7.7) M5 (5) 37 (8) 57 (41) . WT1 expression in the two non-monocytic AML were 0.97 and 1.57 while the WT1 levels observed in the three cases with CD14 + were 0.11, 0.32 and 0.27. Data on CD33 and CD14 from the other four FAB unsubclassified cases were not available. When the WT1 gene expression levels of patients with AML and MDS were compared, the levels in AML subtypes M1, M2 and M3 were significantly higher than those in MDS in both subtypes RAEB and RAEB-T (P = 0.044) and subtype RA (P Ͻ 0.001).
Average peripheral blood GATA-1 expression in all 56 AML cases is 0.29 ± 0.06. A wide variation of GATA-1 levels was observed among AML cases and there is no statistical difference among AML subtypes. Also, no consistent difference in GATA-1 levels was found between the granulocytic subclasses and M4 to M7 subclasses. However, 24 of 56 AML cases coexpressed both WT1 and GATA-1 in higher than normal levels. In our previous report of AML cases whose leukemic cells exhibited chromosome abnormalities involving 16q22, 23 expression of high WT1 and very low GATA-1 levels was found. However, here we report that only 10 of the 56 AML cases expressed higher than normal WT1, but lower than normal GATA-1.
Cytogenetic analyses were done for 52 of 56 AML cases. In 14 of these cases, WT1 expression levels were very high (the levels of у1.0) and details of their cytogenetic findings are shown in Table 6a . Among this group, abnormal karyotypes were found in 11 of 14 cases (77%). In 10 of these 11 cases, two or more types of chromosomal abnormalities were observed. Three or more types of chromosomal abnormalities were found in seven of the 14 high WT1 expressors. Of the 38 patients with AML whose cells expressed WT1 at lower than 1.0, 25 cases (66%) exhibited abnormal karyotypes. Only eight of these 25 cases showed two or more types of chromosomal defects (compared with 10 of 11 in the former group), and only five of the 38 cases whose WT1 expression ranging from normal limit to 0.99 showed three or more types of chromosomal abnormalities. Interestingly, statistical analysis of the relationship between WT1 expression levels and cytogenetic findings revealed that AML cases with high WT1 expression (WT1 у1.0) associated with complicated chromosome abnormalities of two or more types, whereas AML cases with lower WT1 expression (WT1 Ͻ1.0) tend to have normal diploid karyotype or a single type of chromosome aberration ( 2 = 9.35, P = 0.002). Cytogenetic findings of AML cases whose PB cells expressed moderately high WT1 levels (between 0.50 to 0.99) are shown in Table 6b .
The types of chromosome aberration observed in leukemias overexpressing WT1 are noteworthy. Both of the AML cases with an abnormality of chromosome 19p13.3 (patients 58 and 59) (Table 6a ) had very high WT1 expression levels of 1.12 and 1.10, respectively. In patient 58, the abnormality involving the short arm of chromosome 11 (add(11)(p15)) was also found. Abnormal 11p15 was also observed in another patient with AML who had t(11;17)(p15;q23) and in one patient with MDS (patient 36) who also had add (11)(p15), and both of these cases also showed high WT1 expression levels of 0.69 and 0.67, respectively. In AML case No. 65 arising from blastic transformation of CML, significant levels of both WT1 (1.75) and GATA-1 (0.41) were expressed. Again, cytogenetic analysis of this patient revealed complex abnormalities involving t(9;22)(q34;q11), del(11)(q13q21), del(12)(q14), add(16)(q24), del(3)(p11p21) and t(2;17)(p21; p13).
WT1 and GATA-1 expression in acute lymphoblastic leukemia (ALL)
Sixteen of 22 cases of ALL (72.7%) had higher WT1 levels than the normal individuals (P = 0.002) (Figure 2) . The average WT1 level among patients with ALL was 0.43 ± 0.06. Details of FAB classes, immunophenotypes, percentage of PB and BM blasts, WT1 expression levels and cytogenetic findings in each ALL patient are listed in Table 7 . The FAB type L1 and type L2 did not differ in terms of WT1 expression levels, with the means of 0.36 (n = 7) and 0.43 (n = 10), respectively. Of all patients with ALL, B-precursor ALL was diagnosed in 16 of 22 cases, T precursor ALL in two cases and unclassified phenotype in four cases. A patient of B-precursor ALL was diagnosed as pro-B-ALL (CD34 +/or− , C data were not available). Of these 15 B-precursor intermediate ALL cases, six also expressed myeloid markers (CD33 or CD13 or both) and so-called B-precursor/My ALL. Both cases of T-precursor ALL expressed CD7 + , and had high WT1 levels of 0.9 and 1.0. One of these two T-precursor ALL cases also expressed TdT
+ , CD13 + and so-called Tprecursor/My ALL. These mixed B (n = 6) or mixed T (n = 1), precursor/My ALL cases showed relatively higher WT1 expression levels than the cases of pure B-precursor ALL, with average WT1 levels of 0.56 ± 0.13 s.e.m. (n = 7) and 0.36 ± 0.08 s.e.m. (n = 9), respectively. Five of the seven mixed ALL/My phenotypes had WT1 levels above 0.35 whereas this level was observed in only three of the nine Bprecursor-ALL. The immunologic phenotypes were not available in four ALL cases; but three of four showed elevated levels of WT1 expression.
Among six cases with CD10 + and CD19 + , the CD20 phenotype was examined: four were CD20 + without any myeloid markers and the other two cases were CD20 − , both expressed CD13 + . The average WT1 levels were 0.17 in the former four cases and 0.79 in the latter two.
Cytogenetic analysis was done in 17 of 22 ALL cases and chromosome abnormalities were seen in 14 of the 17 cases (82%). Thirteen of these 14 cases with abnormal karyotypes showed elevated WT1 transcript levels, whereas elevation of GATA1 transcript was found in only three cases. Two ALL cases, one with translocation t(9;22)(q34;q11) and another with del (2)(p11.2), showed elevated levels of both WT1 and GATA1 gene transcripts. Chromosome 19p abnormalities were seen in three of the 14 ALL cases with abnormal karyotypes: patient 6 with del(19)(p13.3), patient 10 with t(1;19)(q23;p13) and patient 15 with add (19)(p13), along with hyperdiploid and other complex structural abnormalities, including t(14;18)(q32;q21), add(1)(p36) and add(14)(q32). All three cases exhibited high levels of WT1 transcripts. Seven ALL cases showed chromosomal deletions and high levels of WT1 were expressed in six of these seven cases. The highest WT1 level in the ALL group was observed in a case of T-precursor/My ALL who had del(2)(p11.2). As mentioned earlier, moderately elevated GATA1 was also detected in this patient. High elevation of WT1 levels were also found in the other two deletion cases, one with del(6)(q23), del(13)(q12q22) and another with del(4)(p11). Five B-precursor ALL cases exhibited t(9;22)(q34;q11) and three of five showed high WT1 transcript levels. Since the majority of ALL cases in our study were diagnosed as B-precursor ALL, we did not find t (9;22) in the two cases of T-precursor ALL. WT1 levels within normal limits were observed in four cases with abnormal karyotypes. Conversely, increased WT1 levels were detected in all three cases with normal karyotype. Increased sample size of ALL cases will be necessary to verify the statistical significance of ALL phenotypes in relation to WT1 expression/or cytogenetic findings.
The overall GATA-1 expression in ALL was not different from the normal control, with the average value of 0.19 ± 0.05. Only two out of 20 ALL cases showed increased levels of both WT1 and GATA-1 coexpression (patient 4, WT1 0.65 and GATA-1 1.07; patient 17, WT1 1.03, GATA-1 0.22). Interestingly, the immunophenotype and cytogenetic study of these two patients revealed that patient 4 had mixed B-precursor/My ALL and t(9;22)(q34;q11) while patient 17 had mixed Tprecursor/My ALL and cytogenetic findings showed complex a Immunophenotypes of ALL cases: 'I' early B precursor ALL (pro B ALL); '2' pre-pre B (CALLA)/or pre-B ALL; '3' pre-pre B/or pre-B ALL with myeloid markers; '4' T-precursor ALL; '5' T-precursor ALL with myeloid markers; NA, samples were not available for analysis, or inadequate samples.
numerical and structural abnormalities with deletion of chromosome 2 at 2p11.2. There were inadequate samples for GATA-1 determination in two of 22 ALL cases.
Discussion
WT1 transcript levels in patients with MDS and acute leukemia may be affected by stages of cellular differentiation/maturation, proliferation capacities, cellular lineages, and genetic changes. We and others have previously reported the differences in WT1 transcript levels in various subtypes of AML. [16] [17] [18] 23, 37, 38 Less differentiated subtypes of AML, such as M0 and M1, expressed higher WT1 levels than the more differentiated subtypes. We have presented evidence that WT1 mRNA was produced at higher levels in patients with undifferentiated (M0) and granulocytic AML (M1 to M3) than in patients with the other AML subtypes (M4 to M7). In accordance with Bergmann et al, 39 AML patients with monocytic subtypes (M4, M5) expressed either lower WT1 levels (ours) or the frequency of WT1 expression in (WT1 + ) 39 in AML patients with monocytic subtypes was less. We also found that all cases of M0-M3 (n = 25) and half of M6 and M7 (n = 4) expressed high WT1 levels, whereas Bergmann et al reported WT1
+ in M0, M1, M3 and M6 cases but only 74% of their M2 cases overexpressed WT1 compared to the normal control BM. However, the percentage of blasts and promyelocytes which could affect WT1 levels were not described in their study. By using the sensitive, isotopic-quantitative duplex primed RT-PCR approach, with ␤-actin as an internal control in the same PCR reaction used for amplifying WT1 or GATA-1, we demonstrated a detectable amount of WT1 transcripts in PB mononuclear cells of normal individuals. Bone marrow CD34
+ cells also expressed a substantial level of WT1 15 which has been confirmed by other investigators. 39 , 44 Maurer et al 40 recently reported that WT1 mRNA is equally expressed in blast cells from AML and normal CD34 + progenitors. On the other hand, Inoue et al 41 found that leukemic cells expressed WT1 in the range between 2.4 to 9.3 × 10 −1 and the levels of WT1 expression in normal CD34
+ subsets of bone marrow and cord blood were very low compared to the leukemic cells, although significantly higher than the CD34 − subsets. The observation that WT1 was transiently expressed in normal CD34
+ cells 42 in early hematopoietic differentiation and that it was downregulated during differentiation of leukemic cell lines 43, 44 suggests that the WT1 gene plays a role in hematopoietic differentiation in normal and leukemic cells.
The clinical relevance of WT1 is of current interest. Inoue et al 18, 45 reported the detection of minimal residual disease (MRD) by monitoring of WT1 expression levels in BM and PB and found that peripheral blood samples were superior to bone marrow samples for detection of MRD. 45 Quantitation
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of WT1 expression levels has been proposed as a method to assess the effectiveness of individual treatment and the diagnoses of clinical relapse, 45 as well as prediction of the overall survival of leukemia patients. 39 The normal PB WT1 levels in this study are five to 10 times higher than those determined by Inoue et al 41, 45 but variation in the quantitation procedures used could explain differences in the levels of WT1 expression observed among investigators. We used duplex single reactions for amplifying WT1 and ␤-actin, standard amplification cycles, and lower concentration of ␤-actin relative to WT1 primers. All of these could affect the WT1/␤-actin ratio calculated by different investigators. Optimization of RT-PCR conditions used in our studies was reported previously 15, 23 and only high quality total RNAs were used in order to prevent failure of the RT-PCR reaction from degraded RNA. The ethidium bromide stained PCR products (␤-actin and WT1) from normal controls and patients with MDS and leukemia are apparent in Figure 1 .
To understand a possible interaction between WT1 and GATA-1, a regulator of WT1 expression, we examined WT1 and GATA-1 gene expression in MDS and acute leukemia. Above normal levels of WT1 gene expression were observed in PB and BM of patients with MDS (especially subtypes RAEB and RAEB-T), AML and ALL. MDS-RA (the mildest form of MDS) samples did not show significantly different WT1 expression levels compared with normal controls. Patients with RA presented with reticulocytopenia, oval macrocytes, morphologically normal granulocytes and megakaryocytes in BM and rare blast cells (less than 1% in PB and less than 5% in BM). The more aggressive MDS subtypes RAEB and RAEB-T were examined together in this study because of the limited number of cases. These two MDS subtypes showed obviously higher WT1 expression levels than the normal level and relatively higher than RA (P = 0.086). These subtypes presented with trilineage cytopenias with significant dysmyelopoiesis and dysmegakaryopoiesis. PB and BM blasts are 1-5% and 5-20%, respectively, for RAEB, but Ͼ5% and 20-30%, respectively in RAEB-T. Differences in WT1 expression levels between RA (mean 0.19) and RAEB/RAEB-T subtypes (mean 0.46), along with the similarity of WT1 expression levels between RA and the normal individuals suggests that WT1 gene expression probably increases in the abnormal MDS cells of more severe subtypes. When WT1 gene expression levels of AML and MDS samples were compared, we found that AML (especially subtypes M1, M2, M3) showed even higher WT1 expression levels than MDS in both RAEB/RAEB-T and RA.
Leukemic cells in PB are descendants of their BM ancestors. WT1 gene expression in AML cases with 50% or more BM blasts is higher than that in cases with fewer than 50% BM blasts (P = 0.002, Table 5 ). These results imply that WT1 expression may be directly related to the number of BM blasts which reflect proliferative capacities of leukemia cells. WT1 gene expression may be useful in determining the prognosis of MDS patients whose disease is tending to progress into the more aggressive forms, RAEB and RAEB-T and possibly to acute leukemia. However, further studies are needed before the conclusion is made concerning the predictive value of WT1 expression regarding progression of MDS.
All cases expressed WT1 levels that were significantly greater than normal control levels but less than those of AML. Increased WT1 expression was found in ALL cells expressing both lymphoid and myeloid markers. Five of seven ALL cases (either B-or T-precursor ALL) exhibiting myeloid markers CD33
+ and CD13 + expressed WT1 levels of more than 0.35 while only three of nine cases of B-precursor ALL without myeloid markers reached this level. Combination of this finding with that of our previous work 8, 23 suggests that WT1 expression is cell type-specific and expressed more in myeloid than in lymphoid or monocytic cells. Alternatively, elevated WT1 levels in ALL expressing myeloid markers may simply reflect the early stage of differentiation of their abnormal multipotent leukemic stem cell ancestors that inherited the ability to express both lymphoid and myeloid markers. We and others have demonstrated that leukemias with early differentiation-stage markers express more WT1 than the late stage, more mature leukemias. 18, 23, 37 Our observation that ALL with CD20 − , CD10 + , and CD19 + expresses more WT1 than the ALL with CD20
+ , CD10 + , and CD19 + also supports the hypothesis that WT1 plays role in the stages of cellular differentiation/maturation. Thus, function of WT1 gene may influence both stage of differentiation of the leukemic clones and the specific lineage programme for cellular differentiation.
Expression pattern of transcription factors may reflect the programming for specific lineages. Increased GATA-1 expression was observed in 27 of our 56 AML cases, the frequency comparable to those of Shimamoto et al. 46 In their report, the detectable levels of GATA-1 expression (GATA-1
were found in 30 of 62 AML patients (48.4%). Cell lines exhibiting erythrocytic and megakaryocytic phenotypes expressed GATA-1, and downregulation of GATA-1 in HL-60 cells was found during the process of monocytic differentiation. In addition, AML patients with GATA-1 − showed significantly higher complete remission rate (CR) than the AML patients with GATA-1 + suggesting a prognostic value for GATA-1 expression in AML. In this study, we found that 24 of 56 AML patients showed elevation of both WT1 and GATA-1, whereas only one of 12 MDS and two of 20 ALL showed this type of coexpression. Both cases of ALL which had high WT1-GATA-1 coexpression exhibited myeloid markers. The compilation of these data partly supports the previous studies 19, 22 that WT1 transcription is transactivated by GATA-1 through 3Ј and 5Ј WT1 enhancers in a cell type-specific fashion. These enhancers are responsible for expression of WT1 in erythroid (WT1 3Ј enhancer) and myeloid (WT1 5Ј enhancer) lineages. Several observations suggest that GATA-1 is expressed in the same cell type-specific manner as WT1: high expression of GATA-1 in primary AML and erythrocytic and megakaryocytic cell lines, downregulation of GATA-1 during monocytic differentiation of HL60 cells, 46 downregulation of WT1 during differentiation of K562 cells to erythroid and megakaryocytic cells 43 as well as downregulation of WT1 in HL-60 cells during myelomonocytic differentiation. 44 These findings suggest that GATA-1 and WT1 may have certain regulatory cooperation in terms of the programming for monocytic, erythrocytic and megakaryocytic differentiation from their myeloid progenitors.
Other transcription factors or regulatory mechanisms could affect WT1 expression. For the 32 AML patients whose GATA-1 expression levels were not correlated to WT1 expression levels, GATA-1 may not be necessary for transactivation of WT1 in these patients and WT1 may be regulated by other factors. WT1 is also regulated by c-Myb, 22 PAX8, 47 leukemia inhibitory factor (LIF) 48 and WT1 itself (autoregulation). 49 Zhang et al 22 found that c-Myb can transactivate WT1 hematopoietic specific enhancer by up to five-fold in a co-transfection system, using WT1 enhancer-CAT reporter construct and c-Myb expression vector. We and others 50, 51 previously demonstrated coexpression of WT1 and PAX8 in both renal and hematopoietic neoplastic cell lines and we demonstrated that PAX8 can transactivate WT1 promoter. 47 Upregulation of WT1 gene by LIF in M1 leukemic cells has been reported, 48 and this WT1 activation is associated with monocytic differentiation of the M1 cells. On the other hand, WT1 has also been known to control expression of hematopoietic growth control genes such as CSF-1, TGF␤-1, RAR-␣, c-Myc and bcl-2.
12,52
Coexpression of WT1 and bcl-2 in BM cells of 152 AML patients, and association of this coexpression to therapeutic response and long-term outcome of the AML patients have been reported, suggesting the use of WT1-bcl2 coexpression as a new prognostic factor. WT1 may be a key factor that controls not only the hematopoietic system but also genitourinary organ development. Regulation by WT1 of genes involved in sexual development has recently been reported. Shimamura et al 54 demonstrated that SRY (sex determining region of the Y chromosome) promoter was strongly activated by the WT1 (KTS-) isoform while the AR (androgen receptor) promoter was strongly repressed by this isoform. These findings suggest that WT1 plays an important role in embryonal sexual development and it can function as a repressor or an activator of its target genes.
In conclusion, we report WT1 and GATA-1 expression, cytogenetic findings and specific cellular markers in acute leukemia and myelodysplastic syndrome. High WT1 levels were found in RAEB and RAEB-T types of MDS, and in M0 to M3 types of de novo AML. For ALL, cases with B-, or T-precusor ALL having myeloid markers showed elevation of WT1 levels greater than pure B-precursor ALL. Increased WT1 expression was associated with AML with increased percentage of blasts and leukemic promyelocytes, as well as with MDS and acute leukemia that exhibited complicated chromosome abnormalities. Certain recurrent chromosome changes were detected in MDS and acute leukemia cases with high WT1 expression levels. Increased WT1 and GATA-1 coexpression was observed in 43% of AML cases, but the observation was found in only two out of 20 cases (10%) of ALL and these two cases also expressed myeloid markers. We believe that GATA-1 and WT1 regulatory interaction occurs in a cell type-specific manner playing a greater role in AML than in ALL. This interaction may result in cellular proliferation and/or differentiation of acute leukemias.
